SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 8.42% Stake in FibroGen Inc.
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have reported an 8.42% beneficial ownership stake in FibroGen Inc., holding 8,500,000 shares as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd collectively hold 8,500,000 shares of FibroGen Inc. common stock.
- This represents 8.42% of FibroGen's total outstanding common stock.
- The reporting persons have shared voting power and shared dispositive power over all 8,500,000 shares.
- The percentage of ownership is based on 100,916,956 shares of FibroGen Inc. common stock outstanding as of February 28, 2025, as reported in the Issuer's 10-K filed on March 17, 2025.
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
- Steven Boyd is the managing member of Armistice Capital, LLC.
- This filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as it indicates a significant, passive investment by an institutional entity, which can be interpreted as a vote of confidence in the issuer. However, it's a routine disclosure and doesn't contain operational or financial performance details.
Positives
- A significant stake (8.42%) held by Armistice Capital and Steven Boyd indicates a notable investment and potential confidence in FibroGen Inc.'s long-term prospects.
- The filing certifies that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive investment intent rather than an immediate activist challenge.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by Armistice Capital, LLC and Steven Boyd in FibroGen Inc., a company operating in the biotechnology or pharmaceutical sector. Such filings are common for institutional investors taking substantial, non-controlling stakes in publicly traded companies, often signaling confidence in the company's long-term prospects or a strategic portfolio allocation within the healthcare industry.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor holding 8.42% of the common stock may influence investor perception and potentially stock liquidity.
Key Dates
| Date | Description |
|---|---|
| 2025-02-28 | Date as of which FibroGen Inc.'s outstanding shares (100,916,956) were reported in its 10-K. |
| 2025-03-17 | Date FibroGen Inc. filed its 10-K with the SEC, reporting outstanding shares. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G amendment. |
| 2025-05-15 | Filing date of this Schedule 13G Amendment No. 3. |
Keywords
FibroGen Inc., Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.